MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound

JOURNAL OF CONTROLLED RELEASE

卷:263

Article; Proceedings Paper

Timbie, Kelsie F.¹  Afzal, Umara^2,3,4  Date, Abhijit^2,3  Zhang, Clark^2,3  Song, Ji¹  Miller, G. Wilson⁵  Suk, Jung Soo^2,3  Hanes, Justin^2,3  Price, Richard J.¹ 

[1] Univ Virginia, Dept Biomed Engn, 415 Lane Rd Bldg MR5,Box 800759 Hlth Syst, Charlottesville, VA 22908 USA

[2] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Ctr Nanomed, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA

[4] PMAS Arid Agr Univ, Dept Biochem, Muree Rd, Rawalpindi, Pakistan

[5] Univ Virginia, Dept Radiol & Med Imaging, 480 Ray C Hunt Dr, Charlottesville, VA 22908 USA

关键词: Focused ultrasound;    Blood-brain barrier;    Blood-tumor barrier;    Glioma;    Nanoparticle;    Cisplatin;   

DOI  :  10.1016/j.jconrel.2017.03.017

来源: Elsevier

【 摘 要 】

Systemically administered chemotherapeutic drugs are often ineffective in the treatment of invasive brain tumors due to poor therapeutic index. Within gliomas, despite the presence of heterogeneously leaky microvessels, dense extracellular matrix and high interstitial pressure generate a blood-tumor barrier (BTB), which inhibits drug delivery and distribution. Meanwhile, beyond the contrast MRI-enhancing edge of the tumor, invasive cancer cells are protected by the intact blood-brain barrier (BBB). Here, we tested whether brain-penetrating nanoparticles (BPN) that possess dense surface coatings of polyethylene glycol (PEG) and are loaded with cisplatin (CDDP) could be delivered across both the blood-tumor and blood-brain barriers with MR image-guided focused ultrasound(MRgFUS), and whether this treatment could control glioma growth and invasiveness. To this end, we first established that MRgFUS is capable of significantly enhancing the delivery of similar to 60 nm fluorescent tracer BPN across the blood-tumor barrier in both the 9 L (6-fold improvement) gliosarcoma and invasive F98 (28-fold improvement) glioma models. Importantly, BPN delivery across the intact BBB, just beyond the tumor edge, was also markedly increased in both tumor models. We then showed that a CDDP loaded BPN formulation (CDDP-BPN), composed of a blend of polyaspartic acid (PAA) and heavily PEGylated polyaspartic acid (PAA-PEG), was highly stable, provided extended drug release, and was effective against F98 cells in vitro. These CDDP-BPN were delivered from the systemic circulation into orthotopic F98 gliomas using MRgFUS, where they elicited a significant reduction in tumor invasiveness and growth, as well as improved animal survival. We conclude that this therapy may offer a powerful new approach for the treatment invasive gliomas, particularly for preventing and controlling recurrence. (C) 2017 Elsevier B.V. All rights reserved.

【 授权许可】

Free